Opportunity Information: Apply for RFA MD 18 003
This NIH funding opportunity (RFA-MD-18-003) supports research focused on pre-exposure prophylaxis (PrEP) as an HIV prevention strategy specifically within U.S. health disparity populations. The central aim is not to test a new PrEP clinical intervention in a trial, but to better understand why PrEP use looks the way it does in real communities and healthcare settings. The initiative is designed to uncover the individual, interpersonal, community, and broader societal factors that shape PrEP attitudes, awareness, access, availability, uptake, and adherence. In practice, this means projects should dig into the barriers and facilitators that influence whether people who could benefit from PrEP are able to learn about it, obtain it, start it, and stay on it consistently.
The opportunity explicitly encourages research based in community settings and healthcare delivery settings, reflecting an interest in how PrEP access and sustained use are affected by the environments where people live and receive care. Applicants can propose primary data collection using quantitative methods (for example, surveys or structured assessments) and/or qualitative approaches (such as interviews, focus groups, or ethnographic work). Secondary analyses of existing datasets are also allowed, which can include analyses of clinical records, public health surveillance data, cohort datasets, insurance claims, or other previously collected sources, as long as the work meaningfully addresses the factors that influence PrEP-related outcomes in health disparity groups.
This is an R01 grant mechanism under NIH, and it is labeled "Clinical Trial Not Allowed," meaning the funded work should not be structured as a clinical trial evaluating an intervention’s efficacy or effectiveness. The program is positioned more toward observational, implementation-relevant, and explanatory research that clarifies multilevel drivers of PrEP patterns, rather than running a prospective trial to test an intervention or treatment strategy. The goal is to generate evidence that can inform future programs, policy, service delivery improvements, or targeted implementation strategies aimed at reducing HIV-related disparities.
Eligible applicants are broad and include many types of U.S. organizations and governments. Eligible entities include state, county, and city or township governments; special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; Native American tribal governments (federally recognized); tribal organizations that are not federally recognized; public housing authorities and Indian housing authorities; nonprofits (both 501(c)(3) and non-501(c)(3)); for-profit organizations (other than small businesses); and small businesses. The announcement also highlights additional eligible applicant categories such as historically black colleges and universities (HBCUs), Hispanic-serving institutions, tribally controlled colleges and universities (TCCUs), Alaska Native and Native Hawaiian serving institutions, and Asian American Native American Pacific Islander serving institutions (AANAPISIs). It also indicates that faith-based and community-based organizations, regional organizations, eligible federal agencies, and U.S. territories or possessions may apply, reinforcing the intent to reach institutions closely connected to affected communities.
At the same time, there are clear restrictions related to foreign participation. Non-domestic (non-U.S.) entities (foreign organizations and foreign institutions) are not eligible to apply, and non-domestic components of U.S. organizations are not eligible to apply. However, NIH "foreign components" as defined in the NIH Grants Policy Statement are allowed, which typically means certain parts of the project can involve foreign collaboration or activities if they meet NIH requirements and are appropriately justified, while keeping the applicant organization domestic and compliant with the stated eligibility rules.
The opportunity falls under the Health funding activity category and is associated with CFDA number 93.307. The listed award ceiling is $350,000, and the original closing date for the announcement was February 28, 2018, with a creation date of November 30, 2017. Overall, the program is geared toward generating practical, context-specific knowledge about why PrEP access and adherence remain uneven across populations and settings, and what multilevel factors are driving those gaps, with an emphasis on research that can ultimately help reduce HIV disparities in the United States.Apply for RFA MD 18 003
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "Research on Pre-Exposure Prophylaxis (PrEP) to Prevent HIV in Health Disparity Populations (R01-Clinical Trial Not Allowed)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.307.
- This funding opportunity was created on 2017-11-30.
- Applicants must submit their applications by 2018-02-28. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $350,000.00 in funding.
- Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Frequently Asked Questions (FAQs) - NIH RFA-MD-18-003 (PrEP and HIV Prevention in U.S. Health Disparity Populations)
1) What is this funding opportunity about?
This NIH funding opportunity (RFA-MD-18-003) supports research focused on pre-exposure prophylaxis (PrEP) as an HIV prevention strategy specifically within U.S. health disparity populations. The goal is to better understand why PrEP use looks the way it does in real communities and healthcare settings.
2) What is the main purpose of the research supported by this RFA?
The central aim is to identify and explain the individual, interpersonal, community, and broader societal factors that shape PrEP attitudes, awareness, access, availability, uptake, and adherence among U.S. health disparity populations.
3) Is this opportunity intended to fund a new PrEP clinical intervention trial?
No. The opportunity is not intended to test a new PrEP clinical intervention in a trial. It is focused on observational, explanatory, and implementation-relevant research that clarifies multilevel drivers of PrEP patterns in real-world settings.
4) Are clinical trials allowed under this announcement?
No. This is an NIH R01 opportunity labeled "Clinical Trial Not Allowed," meaning the funded work should not be structured as a clinical trial evaluating an intervention's efficacy or effectiveness.
5) What kinds of PrEP-related outcomes or topics can be studied?
Projects should address factors that influence PrEP attitudes, awareness, access, availability, uptake (starting PrEP), and adherence (staying on PrEP consistently), especially in populations experiencing health disparities in the United States.
6) What does "multilevel factors" mean in this program?
It refers to influences that occur at different levels, including individual factors, interpersonal factors, community factors, and broader societal factors that shape PrEP-related knowledge, attitudes, access, and sustained use.
7) Where should the research take place?
The announcement explicitly encourages research based in community settings and healthcare delivery settings, reflecting an interest in how local environments and care systems affect PrEP access and sustained use.
8) What types of research methods are allowed?
Applicants may propose primary data collection using quantitative methods (such as surveys or structured assessments) and/or qualitative approaches (such as interviews, focus groups, or ethnographic work). Secondary analyses of existing datasets are also allowed.
9) Can applicants use existing data instead of collecting new data?
Yes. Secondary analyses of existing datasets are allowed, as long as the work meaningfully addresses the factors that influence PrEP-related outcomes in health disparity groups.
10) What kinds of existing datasets may be used for secondary analysis?
Examples mentioned include clinical records, public health surveillance data, cohort datasets, insurance claims, or other previously collected sources, provided the analysis addresses PrEP-related factors and outcomes in health disparity populations.
11) What grant mechanism is used for this opportunity?
This opportunity uses the NIH R01 grant mechanism.
12) What is the overall goal or expected impact of the funded research?
The goal is to generate evidence that can inform future programs, policy, service delivery improvements, or targeted implementation strategies aimed at reducing HIV-related disparities in the United States.
13) Who is eligible to apply?
Eligible applicants include a broad range of U.S. organizations and governments, including state, county, and city or township governments; special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; tribal governments (federally recognized); tribal organizations that are not federally recognized; public housing authorities and Indian housing authorities; nonprofits (both 501(c)(3) and non-501(c)(3)); for-profit organizations (other than small businesses); and small businesses.
14) Are community-based and faith-based organizations eligible?
Yes. The announcement indicates that faith-based and community-based organizations may apply.
15) Are minority-serving institutions specifically highlighted as eligible?
Yes. The opportunity highlights additional eligible applicant categories such as historically black colleges and universities (HBCUs), Hispanic-serving institutions, tribally controlled colleges and universities (TCCUs), Alaska Native and Native Hawaiian serving institutions, and Asian American Native American Pacific Islander serving institutions (AANAPISIs).
16) Are U.S. territories or possessions eligible to apply?
Yes. The announcement indicates that U.S. territories or possessions may apply.
17) Can federal agencies apply?
Yes. The announcement indicates that eligible federal agencies may apply.
18) Are foreign (non-U.S.) organizations eligible to apply as the applicant organization?
No. Non-domestic (non-U.S.) entities (foreign organizations and foreign institutions) are not eligible to apply.
19) Can a U.S. organization apply if the work will be conducted through a non-U.S. component of that organization?
No. Non-domestic components of U.S. organizations are not eligible to apply under this opportunity.
20) Are any types of international collaboration allowed?
Yes, NIH "foreign components" as defined in the NIH Grants Policy Statement are allowed, meaning certain parts of the project may involve foreign collaboration or activities if they meet NIH requirements and are appropriately justified, while the applicant organization remains domestic and compliant with eligibility rules.
21) What is the funding activity category for this opportunity?
The funding activity category is Health.
22) What is the CFDA number associated with this program?
The opportunity is associated with CFDA number 93.307.
23) What is the listed award ceiling?
The listed award ceiling is $350,000.
24) What were the key dates for this opportunity?
The creation date for the announcement was November 30, 2017, and the original closing date was February 28, 2018.
25) What kinds of real-world questions is this RFA trying to answer about PrEP?
It is designed to uncover barriers and facilitators that influence whether people who could benefit from PrEP are able to learn about it, obtain it, start it, and remain adherent in real community and healthcare settings, particularly within U.S. health disparity populations.
Browse more opportunities from the same category: Health
Next opportunity: Organic Agriculture Research and Extension Initiative
Previous opportunity: NIDCD Clinical Trials in Communication Disorders (R01-Clinical Trial Required)
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA MD 18 003
Applicants also applied for:
Applicants who have applied for this opportunity (RFA MD 18 003) also looked into and applied for these:
| Funding Opportunity |
|---|
| NHLBI Clinical Trial Pilot Studies (R34 - Clinical Trial Optional) Apply for PAR 18 463 Funding Number: PAR 18 463 Agency: National Institutes of Health Category: Health Funding Amount: $225,000 |
| Cooperative Centers on Human Immunology (U19 Clinical Trial Optional) Apply for RFA AI 17 040 Funding Number: RFA AI 17 040 Agency: National Institutes of Health Category: Health Funding Amount: $2,400,000 |
| Understanding Immunopathogenesis of Tuberculosis in HIV-1 Infected and Exposed Children (R01 Clinical Trial Not Allowed) Apply for RFA AI 17 039 Funding Number: RFA AI 17 039 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NINDS Advanced Postdoctoral Career Transition Award to Promote Diversity in Neuroscience Research (K22) - Clinical Trial Not Allowed Apply for PAR 18 469 Funding Number: PAR 18 469 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NINDS Advanced Postdoctoral Career Transition Award to Promote Diversity in Neuroscience Research (K22) - Clinical Trial Required Apply for PAR 18 468 Funding Number: PAR 18 468 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Initiation of a Mental Health Family Navigator Model to Promote Early Access, Engagement and Coordination of Needed Mental Health Services for Children and Adolescents (R01- Clincal Trial Required) Apply for PAR 18 428 Funding Number: PAR 18 428 Agency: National Institutes of Health Category: Health Funding Amount: $500,000 |
| Clinical and Translational Science Award U54 (Clinical Trial Optional) Apply for PAR 18 464 Funding Number: PAR 18 464 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Pilot Effectiveness Trials for Post-Acute Interventions and Serivces to Optimize Longer-Term Outcomes (R34-Clinical Trials Required) Apply for PAR 18 431 Funding Number: PAR 18 431 Agency: National Institutes of Health Category: Health Funding Amount: $225,000 |
| NINDS Faculty Development Award to Promote Diversity in Neuroscience Research (K01) - Clinical Trial Not Allowed Apply for PAR 18 490 Funding Number: PAR 18 490 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NINDS Faculty Development Award to Promote Diversity in Neuroscience Research (K01) - Clinical Trial Required Apply for PAR 18 486 Funding Number: PAR 18 486 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Prevention and Treatment Research to Address HIV/AIDS Disparities in Women in the US (R01-Accepting applications that either propose or do not propose clinical trial(s)) Apply for RFA MD 18 004 Funding Number: RFA MD 18 004 Agency: National Institutes of Health Category: Health Funding Amount: $350,000 |
| NIBIB Supplements to NCATS CTSA Programs for Translational Research Teams of Quantitative Researchers and Clinician-Scientists (Admin Supp) Apply for PA 18 426 Funding Number: PA 18 426 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| First in Human and Early Stage Clinical Trials of Novel Investigational Drugs or Devices for Psychiatric Disorders (U01-Clinical Trial Required) Apply for PAR 18 427 Funding Number: PAR 18 427 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Effectiveness Trials for Post-Acute Interventions and Services and Services to Optimize Longer-Term Outcomes (R01-Clinical Trials Required) Apply for PAR 18 430 Funding Number: PAR 18 430 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NEI Audacious Goals Initiative: Translation-Enabling Models to Evaluate Survival and Integration of Regenerated Neurons in the Visual System (U24 Clinical Trials Not Allowed) Apply for RFA EY 17 003 Funding Number: RFA EY 17 003 Agency: National Institutes of Health Category: Health Funding Amount: $1,000,000 |
| Detecting and Preventing Suicide Behavior, Ideation and Self-Harm in Youth in Contact with the Juvenile Justice System (R01- Clinical Trial Required) Apply for PAR 18 479 Funding Number: PAR 18 479 Agency: National Institutes of Health Category: Health Funding Amount: $500,000 |
| NIDCR Dental Specialty and PhD Program (DSPP)(K12-Clinical Trials Not Allowed) Apply for RFA DE 18 012 Funding Number: RFA DE 18 012 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NIDCD Early Career Research(ECR) Award (R21 - Clinical Trials Optional) Apply for PAR 18 487 Funding Number: PAR 18 487 Agency: National Institutes of Health Category: Health Funding Amount: $100,000 |
| Exosomes: From Biogenesis and Secretion to the Early Pathogenesis of Alzheimer's Disease (R01 - Clinical Trial Not Allowed) Apply for RFA AG 18 027 Funding Number: RFA AG 18 027 Agency: National Institutes of Health Category: Health Funding Amount: $500,000 |
| Deciphering the Molecular Landscape of Lung Aging in Humans (U01 - Clinical Trial Not Allowed) Apply for RFA HL 19 012 Funding Number: RFA HL 19 012 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA MD 18 003", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.